AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
AZN•AstraZeneca plans to save about $1.5 billion annually over three years, reinvesting mainly in its drug pipeline, and expects up to $2 billion in one-time restructuring charges. Third-quarter revenue rose 7% to $16.21 billion and core earnings were $2.79 per share, topping forecasts; the company maintained its 2026 outlook.
1. Savings and pipeline investment
AstraZeneca unveiled a three-year plan to save about $1.5 billion annually and reinvest the savings mainly in its pipeline of more than 180 projects. It expects up to $2 billion in one-time restructuring charges. Executives said some departments face cutbacks or restructuring while others will re-skill and hire; the company expects net job growth across different areas.
2. Quarterly results beat forecasts
Third-quarter core earnings were $2.79 per share as revenue rose 7% at constant exchange rates to $16.21 billion, above analysts’ forecasts of $2.59 per share and $15.94 billion. Oncology revenue increased 17% to $7.77 billion, including a 35% rise in Enhertu sales to $969 million and a 26% increase in Imfinzi sales to about $2 billion. Farxiga sales fell 25% to $1.61 billion. AstraZeneca maintained its 2026 outlook.
3. Growth targets and outlook
CEO Pascal Soriot said the company remained on track for its 2030 ambition and to sustain growth through the next decade. AstraZeneca is targeting $80 billion in annual revenue by 2030, a goal that relies in part on more than 25 blockbuster medicines. The company says late-stage trial results expected in 2027 could generate more than $20 billion in peak annual sales.
